Allergy Therapeutics PLC (AGY)

Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

6.50p

Buy

7.50p

arrow-up0.00p (+0.00%)

Prices updated at 16 May 2025, 16:35 BST
| Prices minimum 15 mins delay
|
Prices in GBX
Allergy Therapeutics PLC is a pharmaceutical products company. It develops therapies for allergy based diseases, having its primary market in Germany.
FTSE All-Share
arrow-up0.59%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Chairman
Mr. Peter Sinclair Jensen
CEO
Mr. Manuel Llobet
Most recent earnings
30 Jun 2024
Fiscal year end
30 Jun 2024
Employees
602
Head office
Dominion Way
Worthing
United Kingdom
BN14 8SA
mobile
+44 1903844700
letter
infoservices@allergytherapeutics.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Dr. Babatunde Adekunle Otulana
Non-Executive Director, Senior Independent Director
-
Mr. Peter Sinclair Jensen
Non-Executive Director, Chairman
-
Mr. Zheqing Shen
Non-Executive Director
-
Mr. Anthony Michael Parker
Non-Executive Director
-
Mr. Shaun Furlong
Executive Director, Chief Financial Officer
-
Mr. Manuel Llobet
Executive Director, Chief Executive Officer
-

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
Lazard Asset Management Ltd1,068,869
Lazard Multicap UK Income Fund1,068,869
Acadian Asset Management LLC-

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
21 Jan 2025Purchase
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.